semaglutide obesity phase 3 7·2 mg was modestly superior to placebo and 2·4 mg (#wegovy) for #WeightLoss in adults with obesity, while retaining a favourable risk–benefit profile. We recently had the lead author on the Advancements in Clinical Research and

Semaglutide, a drug treatment for Diabetes, was FDA-approved in 2021 for weight loss and chronic weight management

The efficacy and safety of -nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: A randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial

For most, combining retatrutide with consistent physical activity has been an incremental journey, with its victories and bruises

On average, patients can expect to lose 15-20% of their body weight when using oral GLP-1 weight loss medications

Mastering this technique is a core competency for any serious researcher in this field

Nutrire 49 , 26 (2024)